Retrophin Inc (RTRX) COO Sells $35,916.00 in Stock

Retrophin Inc (NASDAQ:RTRX) COO Neil F. Mcfarlane sold 1,968 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $18.25, for a total transaction of $35,916.00. Following the sale, the chief operating officer now directly owns 27,972 shares in the company, valued at approximately $510,489. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of RTRX traded up $0.01 during mid-day trading on Thursday, reaching $18.57. 591,400 shares of the company’s stock were exchanged, compared to its average volume of 372,079. The company has a current ratio of 4.57, a quick ratio of 4.52 and a debt-to-equity ratio of 0.69. The firm has a market cap of $740.47 million, a PE ratio of -7.31 and a beta of 0.91. Retrophin Inc has a 52-week low of $17.53 and a 52-week high of $33.00.

Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.41). The business had revenue of $39.57 million for the quarter, compared to analysts’ expectations of $41.40 million. Retrophin had a negative return on equity of 41.38% and a negative net margin of 75.75%. The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.14) earnings per share. As a group, equities research analysts forecast that Retrophin Inc will post -3.02 EPS for the current fiscal year.

A number of research firms have weighed in on RTRX. Zacks Investment Research cut shares of Retrophin from a “hold” rating to a “sell” rating in a report on Tuesday. BidaskClub raised shares of Retrophin from a “sell” rating to a “hold” rating in a report on Thursday, March 14th. Svb Leerink reissued an “outperform” rating on shares of Retrophin in a report on Tuesday, February 26th. ValuEngine cut shares of Retrophin from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 17th. Finally, William Blair reissued an “outperform” rating on shares of Retrophin in a report on Wednesday, April 17th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $45.67.

Several institutional investors and hedge funds have recently made changes to their positions in RTRX. AQR Capital Management LLC grew its position in shares of Retrophin by 117.5% during the third quarter. AQR Capital Management LLC now owns 29,132 shares of the biopharmaceutical company’s stock worth $837,000 after acquiring an additional 15,740 shares during the last quarter. Legal & General Group Plc grew its position in shares of Retrophin by 33.5% during the third quarter. Legal & General Group Plc now owns 13,541 shares of the biopharmaceutical company’s stock worth $389,000 after acquiring an additional 3,395 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Retrophin by 1.4% during the third quarter. Vanguard Group Inc. now owns 1,928,602 shares of the biopharmaceutical company’s stock worth $55,409,000 after acquiring an additional 26,016 shares during the last quarter. Federated Investors Inc. PA grew its position in shares of Retrophin by 4.3% during the third quarter. Federated Investors Inc. PA now owns 93,495 shares of the biopharmaceutical company’s stock worth $2,686,000 after acquiring an additional 3,855 shares during the last quarter. Finally, Vanguard Group Inc grew its position in shares of Retrophin by 1.4% during the third quarter. Vanguard Group Inc now owns 1,928,602 shares of the biopharmaceutical company’s stock worth $55,409,000 after acquiring an additional 26,016 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Retrophin Inc (RTRX) COO Sells $35,916.00 in Stock” was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/16/retrophin-inc-rtrx-coo-sells-35916-00-in-stock.html.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Further Reading: What is the Difference Between Common Shares and Convertible Shares?

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.